NCT01999309View on ClinicalTrials.gov

Simvastatin Addition for Patients With Recent-onset Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 19, 2019

Study Completion Date

December 19, 2019

Conditions
SchizophreniaSchizoaffective DisorderSchizophreniform DisorderPsychosis NOS
Interventions
DRUG

Simvastatin

The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.

DRUG

Placebo

Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.

Trial Locations (2)

9700 RB

University Medical Center Groningen, Groningen

3584 CX

University Medical Center Utrecht, Utrecht

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Iris Sommer

OTHER

NCT01999309 - Simvastatin Addition for Patients With Recent-onset Schizophrenia | Biotech Hunter | Biotech Hunter